SXTC SXT Pharmaceuticals: Enterprise Value to EBITDA Ratio
China SXT Pharmaceuticals specializes in the development of traditional Chinese medicine pharmaceuticals. This EV/EBITDA price chart shows a value of 0.00, which is significant amid trade restrictions forcing the business to operate exclusively within the PRC. Demand for such products remains independent of economic cycles or seasonality. Meanwhile, its micro-cap status triggers investor caution and a certain level of brand image instability.
Comprehensive metric breakdowns and analytics for China SXT Pharmaceuticals, Inc. (SXTC)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity China SXT Pharmaceuticals|SXTC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital China SXT Pharmaceuticals|SXTC - Company Total Debt|Debts to Book Capitalization SXT Pharmaceuticals|SXTC - Company Long-Term Loans and Borrowings|Company Short-Term Debts China SXT Pharmaceuticals|Quick Liquidity sxtchina.com
- financial results and valuation multiples details:
SXTC - Company Profit|Projected Future Earnings China SXT Pharmaceuticals|SXTC - P/E Multiple|Projected Price to Earnings China SXT Pharmaceuticals|SXTC - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SXT China|SXTC - Operating income before deduction of amortization|Net earnings per share for the last 12 months China SXT Pharmaceuticals|SXTC - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months sxtchina.com|SXTC - Net earnings per one share growth for the current year|Expected earnings per share growth for next year China SXT Pharmaceuticals
- company sales and revenue statistics:
Analysis of all company metrics:China SXT Pharmaceuticals, Inc. SXTC
The investment attractiveness of China SXT Pharmaceuticals (SXTC) is based on stable demand for traditional medicine. An EV/EBITDA multiple of 0.00 assesses the business value, including net debt, relative to operating profit before depreciation and amortization. By analyzing the enterprise value to EBITDA trend, an investor identifies the impact of leverage on capitalization. This indicator helps determine the fair premium for the stability of this cash cow within the pharmaceutical sector.
Key competitors
Haleon Group - Enterprise Value to EBITDA Ratio|Kenvue (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|Jyong Biotech - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals Inc - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company PLC) - EV/EBITDA Multiple|Company Value to EBITDA alvotech.com ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia (LQDA)|GLPG (Galapagos) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals Inc)|MNKD - Enterprise Value to EBITDA Ratio|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PCRX - EV/EBITDA Multiple|ARS Pharmaceuticals Inc (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Theravance Biopharma Inc (TBPH)|AQST (aquestive.com) - EV/EBITDA Multiple|SCPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|Tonix Pharmaceuticals Holding Corp. - Enterprise Value to Operating Income Before Depreciation|eupraxiapharma.com - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHST|invizyne.com - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ORMP (Oramed Pharmaceuticals Inc.)|ENTX: EV/EBITDA Multiple|MindWalk Holdings Inc. (HYFT) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma|Enterprise Value to Operating Income Before Depreciation CPIX (Cumberland Pharmaceuticals Inc.)|EV/EBITDA Multiple QNTM|Total Company Value to Operating Income Before Depreciation Ratio FibroGen Corporation|EV/EBITDA Multiple TELO (Telomir Pharmaceuticals Corp)|RANI (Rani Therapeutics Inc) - Company Value to Operating Income Before Depreciation Ratio|SNYR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RLYB (Rallybio)|LEXX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulmatrix, Inc.|PTHL (Pheton Holdings Ltd) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APM|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple Impact BioMedical, Inc. (IBO)|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals)|Business Value to Operating Income Before Depreciation YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTO - EV/EBITDA Multiple|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio OPTN (OptiNose)|PIRS (Pieris Pharma) - EV/EBITDA Multiple|Procaps Group Corp - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|qlsyy.net (QLI) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ACELYRIN SLRN|TFFP (TFF Pharmaceuticals, Inc.) - Company Value to Operating Income Before Depreciation Ratio
